Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
35.6M
-
Shares change
-
+260K
-
Total reported value, excl. options
-
$1.63B
-
Value change
-
+$1.14M
-
Put/Call ratio
-
0.89
-
Number of buys
-
78
-
Number of sells
-
-76
-
Price
-
$45.85
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2018
208 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2018.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.6M shares
of 49.6M outstanding shares and own 71.83% of the company stock.
Largest 10 shareholders include Vanguard Group Inc (2.82M shares), ORBIMED ADVISORS LLC (2.71M shares), BlackRock Inc. (2.62M shares), Consonance Capital Management LP (2.3M shares), JANUS HENDERSON GROUP PLC (2.15M shares), STATE STREET CORP (2.02M shares), Partner Fund Management, L.P. (1.85M shares), FMR LLC (1.38M shares), venBio Select Advisor LLC (1.15M shares), and CITADEL ADVISORS LLC (1.12M shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.